Umer Raffat
Stock Analyst at Evercore ISI Group
(2.28)
# 1,546
Out of 4,422 analysts
19
Total ratings
56.25%
Success rate
-5.48%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $1.93 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $6.06 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $7.98 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $24.10 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $9.48 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical | Upgrades: Outperform | n/a | $15.74 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $10.10 | - | 2 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $14.65 | - | 1 | Mar 7, 2023 | |
| LEGN Legend Biotech | Initiates: Outperform | n/a | $45.72 | - | 1 | Nov 2, 2022 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Outperform | n/a | $42.06 | - | 1 | Sep 13, 2022 | |
| OGN Organon & Co. | Initiates: Outperform | n/a | $20.37 | - | 1 | Jun 10, 2021 | |
| KOD Kodiak Sciences | Initiates: Outperform | n/a | $3.83 | - | 1 | Mar 12, 2021 | |
| VOR Vor Biopharma | Initiates: Outperform | n/a | $1.85 | - | 1 | Mar 3, 2021 | |
| AMGN Amgen | Upgrades: Outperform | n/a | $307.31 | - | 1 | Jan 21, 2020 | |
| PIRS Pieris Pharmaceuticals | Initiates: Outperform | $1,040 | $11.14 | +9,235.73% | 1 | Mar 19, 2018 | |
| DERM Journey Medical | Initiates: Outperform | n/a | $3.57 | - | 1 | Jun 30, 2017 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | n/a | $110.70 | - | 1 | Feb 23, 2017 |
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $1.93
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.06
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.98
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $24.10
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $9.48
Upside: -
Teva Pharmaceutical
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $15.74
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $10.10
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $14.65
Upside: -
Legend Biotech
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $45.72
Upside: -
Cerevel Therapeutics Holdings
Sep 13, 2022
Initiates: Outperform
Price Target: n/a
Current: $42.06
Upside: -
Organon & Co.
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.37
Upside: -
Kodiak Sciences
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.83
Upside: -
Vor Biopharma
Mar 3, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.85
Upside: -
Amgen
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $307.31
Upside: -
Pieris Pharmaceuticals
Mar 19, 2018
Initiates: Outperform
Price Target: $1,040
Current: $11.14
Upside: +9,235.73%
Journey Medical
Jun 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Jazz Pharmaceuticals
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $110.70
Upside: -